<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073944</url>
  </required_header>
  <id_info>
    <org_study_id>BIOCRYST-1777BC-101</org_study_id>
    <secondary_id>CDR0000341332</secondary_id>
    <secondary_id>CCF-5909</secondary_id>
    <nct_id>NCT00073944</nct_id>
  </id_info>
  <brief_title>BCX-1777 in Treating Patients With Refractory Cancer</brief_title>
  <official_title>Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for&#xD;
      their growth.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have&#xD;
      refractory cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of BCX-1777 in patients with refractory T-cell or&#xD;
           non-T-cell malignancies.&#xD;
&#xD;
        -  Determine the safety and dose-limiting toxicity of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the pharmacokinetics of single oral and single and multiple IV doses of this&#xD;
           drug in these patients.&#xD;
&#xD;
        -  Determine the oral bioavailability of this drug in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the antitumor activity of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized, dose-escalation, multicenter study.&#xD;
&#xD;
        -  Courses 1 and 2: Patients receive oral BCX-1777 on days 1 and 15* and BCX-1777 IV over&#xD;
           30 minutes on days 8* and 22*.&#xD;
&#xD;
        -  Course 3: Beginning approximately 6 days* after the completion of courses 1 and 2,&#xD;
           patients receive BCX-1777 IV over 30 minutes once daily on days 1-5 and 8-12 (total of&#xD;
           10 doses).&#xD;
&#xD;
      NOTE: *+/- 1 day&#xD;
&#xD;
      Patients with stable disease or better and no dose-limiting toxicity (DLT) may receive an&#xD;
      additional 10-dose treatment course (as in course 3) after a 10- to 16-day drug-free&#xD;
      interval.&#xD;
&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of BCX-1777 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience DLT.&#xD;
&#xD;
      Patients are followed at 14 and 30 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>forodesine hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Hematologic malignancy that is refractory to at least 1 prior curative treatment&#xD;
&#xD;
               -  Non-hematologic tumor that is refractory to at least 2 prior therapies, with or&#xD;
                  without measurable disease, including the following:&#xD;
&#xD;
                    -  Gastrointestinal adenocarcinoma of 1 of the following sites:&#xD;
&#xD;
                         -  Pancreatic&#xD;
&#xD;
                         -  Biliary&#xD;
&#xD;
                         -  Gastric&#xD;
&#xD;
                         -  Colorectal&#xD;
&#xD;
                         -  Esophageal&#xD;
&#xD;
                    -  Melanoma&#xD;
&#xD;
                    -  Ovarian cancer&#xD;
&#xD;
                    -  Astrocytoma brain tumor&#xD;
&#xD;
          -  Not immediately eligible for any other treatment that would be potentially curative or&#xD;
             life-prolonging, in the opinion of the investigator&#xD;
&#xD;
               -  Patients who may be candidates for future bone marrow transplantation are&#xD;
                  eligible&#xD;
&#xD;
          -  No brain metastases (other than astrocytomas)&#xD;
&#xD;
          -  No clinically significant pleural effusion&#xD;
&#xD;
          -  No complete tumor obstruction (e.g., bronchus, ureter, or bowel)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 50-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 3,500/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 50,000/mm^3&#xD;
&#xD;
          -  Hematocrit stable without the need for transfusion (epoetin alfa support allowed)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN) (unless due to Gilbert's&#xD;
             syndrome)&#xD;
&#xD;
          -  SGOT and SGPT less than 2 times ULN&#xD;
&#xD;
          -  No active hepatitis B or C&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No American Heart Association class III or IV cardiac disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active systemic infection requiring IV antibiotics&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided the patient is on a stable regimen&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
               -  No grade 2-4 toxicity&#xD;
&#xD;
          -  More than 3 weeks since prior antineoplastic and/or investigational therapy&#xD;
&#xD;
          -  No other concurrent systemic antineoplastic or investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Shalaurov, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Inveresk Research Group, Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2004</verification_date>
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>May 29, 2013</last_update_submitted>
  <last_update_submitted_qc>May 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2013</last_update_posted>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>chronic eosinophilic leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>chronic neutrophilic leukemia</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>Waldenström macroglobulinemia</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the stomach</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult glioblastoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult subependymoma</keyword>
  <keyword>adenocarcinoma of the extrahepatic bile duct</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

